
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
about 26 years ago
Participating Facultyabout 26 years ago
Introductionabout 26 years ago
HEDIS Measure for the Management of Menopauseabout 26 years ago
Medical Affairs / Provider Relations Team Recommendationsabout 26 years ago
Quality Management Team Recommendationsabout 26 years ago
Pharmacy Team Recommendationsabout 26 years ago
Marketing / Member Relations Team Recommendationsabout 26 years ago
Patient Education Team Recommendations





